Withdrawal and discontinuation phenomena associated with tranylcypromine: A systematic review

Pharmacopsychiatry

Volumn 46, Issue 4, 2013, Pages 123-129

  Gahr, M ^a   Schonfeldt Lecuona C ^a   Kolle M A ^a   Freudenmann, R W ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

antidepressants; delirium; Jatrosom; monoamine oxidase inhibitors; Parnate; psychopharmacotherapy

Indexed keywords

TRANYLCYPROMINE;

ABDOMINAL CRAMP; ADVERSE OUTCOME; AGITATION; CLINICAL FEATURE; COHORT ANALYSIS; DELIRIUM; DEPRESSION; DIARRHEA; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERSALIVATION; INSOMNIA; NAUSEA; PRIORITY JOURNAL; RELAPSE; RESTLESSNESS; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DELIRIUM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; THROMBOCYTOPENIA; TRANYLCYPROMINE; YOUNG ADULT;

EID: 84878808667     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1333265     Document Type: Review

References (86)

1. Parker G., Wilhelm K., Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. J Clin Psychiatry: 2001; 62 17 25
2. Stewart J., Thase M. Treating DSM-IV depression with atypical features. J Clin Psychiatry: 2007; 68 e10
3. Pae C., Tharwani H., Marks D. et al. Atypical depression: a comprehensive review. CNS Drugs: 2009; 23 1023 1037
4. Amsterdam J., Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression - a retrospective study. J Affect Disord: 2005; 89 183 188 (Pubitemid 41740846)
5. Baker G., Coutts R., McKenna K. et al. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatr Neurosci: 1992; 17 206 214 (Pubitemid 23141096)
6. Shih J., Chen K. Regulation of MAO-A and MAO-B gene expression. Curr Med Chem: 2004; 11 1995 2005 (Pubitemid 38967725)
7. Billett E. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology: 2004; 25 139 148 (Pubitemid 38044175)
8. Kalgutkar A., Dalvie D., Castagnoli N. et al. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isoenzymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol. 2001; 14 1139 1162
9. Philips S., Boulton M. The effects of monoamine oxidase inhibitors on some arylalkylamines in rat striatum. J Neurochem: 1979; 33 159 167 (Pubitemid 9233922)
10. Boulton M., Juorio A. Brain trace amines. In: Lajtha A. ed. Handbook of Neurochemistry. New York Plenum Press: 1982; 189 222
11. Baker G., Martin I., Mitchel P. The effects of some indolalkylamines on the uptake and release of 5-hydroxytryptamine in rat striatum. Br J Pharmacol: 1977; 61 151P 152P (Pubitemid 8186582)
12. Raiteri M., Del Carmine R., Bertollini A. et al. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol: 1977; 41 133 142
13. Paterson I., Boulton M. Beta-phenylethylamine enhances single cortical neurone responses to noradrenaline in the rat. Brain Ress Bull: 1988; 20 173 177 (Pubitemid 19017203)
14. Paterson I., Iurio A., Boulton M. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem: 1990; 55 1827 1837 (Pubitemid 120021808)
15. Jones R. Tryptamine: a neuromodulator or neurotransmitter in mammalian brain? Prog Neurobiol: 1982; 19 117 139
16. Jones R. Trace biogenic amines: a possible functional role in the CNS. Trends Pharmacol Sci: 1983; 4 426 429
17. Beavan T. The cheese reaction. Lancet: 1964; 1 540
18. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet: 1963; 2 849 850
19. Asatoor A., Levi A., Milne M. Tranylcypromine and cheese. Lancet: 1963; 54 733 734
20. Graham W. Hypertension caused by tranylcypromine and cheese. JAMA: 1964; 188 782
21. Cuthill J., Griffiths A., Powell D. Death associated with tranylcypromine and cheese. Lancet: 1964; 1 1076 1077
22. Bethune N., Burrell R., Culpan R. Headache associated with monoamine oxidase inhibitors. Lancet: 1963; 2 1233 1234
23. Horwitz D., Lovenberg W., Engelman K. et al. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA: 1964; 188 1108 1110
24. Adli M., Philhatsch M., Bauer M. et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistent depression. Pharmacopsychiatry: 2008; 41 252 257
25. McGrath P., Stewart J., Fava M. et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry: 2006; 163 1531 1541 quiz 1666 (Pubitemid 44465752)
26. Amsterdam J., Berwish N. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry: 1989; 22 21 25 (Pubitemid 19053581)
27. Glaxo-Smith-Kline. Parnate. Prescribing information: 2010
28. Aristo-Pharma. Jatrosom N. Prescribing information: 2010
29. Degner D., Porzig J., Ruther E. et al. Serotonin syndrome with severe hyperthermia after ingestion of tranylcypromine combined with serotinin reuptake inhibitors and tyramine-rich food in a case of suicide. Pharmacopsychiatry: 2010; 43 284 285
30. Gillman P. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry: 2006; 59 1046 1051 (Pubitemid 43849654)
31. Gillman P. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol (Oxf): 2011; 25 423 429
32. Tuomisto J., Tuomisto L., Smissman E. Conformation study of the inhibition of monoamine uptake in rat brain synaptosomes. Ann Med Exp Biol Fenn: 1973; 51 51 58
33. Tuomisto J., Smith D. Effects of tranylcypromine enantiomers on monoamine uptake and release and imipramine binding. J Neural Transm: 1986; 65 135 145 (Pubitemid 16160393)
34. Frieling H., Bleich S. Tranylcypromine: new perpectives of an "oldo" drug. Eur Arch Psychiatry Clin Neurosci: 2006; 256 268 273 (Pubitemid 44285049)
35. Le Gassicke J., Ashcroft G., Eccleston D. et al. The clinical state, sleep and amine metabolism of a tranylcypromine («Parnate») addict. Br J Psychiatry: 1965; 111 357 364
36. Le Gassicke J. Trancylcypromine. Lancet: 1963; 281 269 270
37. Mielczarek J., Johnson J. Tranylcypromine. Lancet: 1963; 281 388 389
38. Morgan D. Tranylcypromine. Lancet: 1963; 281 389
39. Szelényi A., Albrecht J. Tranylcypromine abuse associated with an isolated thrombocytopenia. Pharmacopsychiatry: 1998; 31 238 240 (Pubitemid 29022043)
40. Vartzopoulos D., Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry: 1991; 158 856 857
41. Griffin N., Draper R., Webb M. Addiction to tranylcypromine. Br Med J (Clin Res Ed): 1981; 283 346 (Pubitemid 12250670)
42. Briggs N., Jefferson J., Koenecke F. Tranylcypromine addiction: a case report and review. J Clin Psychiatry: 1990; 51 426 429 (Pubitemid 20359852)
43. Bellon A., Coverdale J. Delirium, thrombocytopenia, insomnia, and mild liver damage associated with MAOI withdrawal. Eur J Clin Pharmacol: 2009; 65 1269 1270
44. Halle M., Dilsaver S. Tranylcypromine withdrawal phenomena. J Psychiatr Neurosci: 1993; 18 49 50 (Pubitemid 23139401)
45. Chatterjee A., Tosyali M. Thrombocytopenia and delirium associated with tranylcypromine overdose. J Clin Psychopharmacol: 1995; 15 143 144
46. Pennings E., Verkes R., de Koning J. et al. Tranylcypromine intoxication with malignant hyperthermia, delirium, and thrombocytopenia. J Clin Psychopharmacol: 1997; 17 430 432 (Pubitemid 27414405)
47. Davids E., Röschke J., Klawe C. et al. Tranylcypromine abuse associated with delirium and thrombocytopenia. J Clin Psychopharmacol: 2000; 20 270 271 (Pubitemid 30202376)
48. Dilsaver S. Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena. Prog Neurpsychopharmacol Biol Psychiatry: 1990; 14 137 161 (Pubitemid 20078457)
49. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry: 1997; Suppl 7 17 21 discussion 22
50. Charney D., Heninger G., Sternberg D. et al. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. Br J Psychiatry: 1982; 141 377 386 (Pubitemid 12030834)
51. Schatzberg A. F., Blier P., Delgado P. L. et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry: 2006; 67 04 27 30 (Pubitemid 43764535)
52. Dilsaver S. Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatr Scand: 1988; 78 1 7
53. th ed. Washington, DC American Psychiatric Association: 2000
54. Eyer F., Jetzinger E., Pfab R. et al. Withdrawal from high-dose tranylcypromine. Clin Toxicol (Phila): 2008; 46 261 263 (Pubitemid 351398404)
55. Brady K., Lydiard R., Kellner C. Tranylcypromine abuse. Am J Psychiatry: 1991; 148 1268 1269
56. Abdi S., Fishman S. Acute exacerbation of depression after discontinuation of monoamine oxidase inhibitor prior to cardiac surgery. Anesth Analg: 1996; 83 656 657 (Pubitemid 26296386)
57. Absher J., Black D. Tranylcypromine withdrawal delirium. J Clin Psychopharmacol: 1988; 8 379 380
58. Ben-Arie O., George G. A case of tranylcypromine ('Parnate') addiction. Br J Psychiatry: 1979; 135 273 274 (Pubitemid 9244813)
59. Cramer H., Ohlmeier D. Ein Fall von Tranycypromine- und Trifluoperazin-(Jatrosom)-Sucht: Psychopathologische, schlafphysiologische und biochemische Untersuchungen. Arch Psych ges Neurol: 1967; 210 182 197
60. Shaikh W., Fuls K. Tranylcypromine dependence and withdrawal. Aust N Z J Psychiatry: 2009; 43 580 581
61. Shopsin B., Kline N. Monoamine oxidase inhibitors: potential for drug abuse. Biol Psychiatry: 1976; 11 451 456
62. Westermeyer J. Addiction to tranylcypromine (Parnate): a case report. Am J Drug Alcohol Abuse: 1989; 15 345 350 (Pubitemid 19195566)
63. Thorp M., Toombs D., Harmon B. Monoamine oxidase inhibitor overdose. West J Med: 1997; 166 275 277 (Pubitemid 27215194)
64. Boyer E., Shannon M. The serotonin syndrome. N Engl J Med: 2005; 352 1112 1120
65. Brubacher J., Hoffmann R., Lurin M. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Hum Toxicol: 1996; 38 358 361 (Pubitemid 26322023)
66. th ed. London Rutledge: 1995; 140 189
67. Robinson D. High-dose monoamine-oxidase inhibitor therapy JAMA: 1983; 250 2212
68. Youdim M., Aronson J., Blau K. et al. Tranylcypromine ("Parnateo") overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med: 1979; 9 377 382 (Pubitemid 9198806)
69. Keck P. J., Carter W., Nierenberg A. et al. Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. J Clin Psychiatry: 1991; 52 250 254
70. Mutschler E., Möhrke W. Kinetics of MAO inhibitors. Mod Probl Pharmacopsychiatry: 1983; 19 126 134
71. Sherry R., Rauw G., McKenna K. et al. Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine. J Affect Disord: 2000; 61 23 29
72. Jefferson J. Is tranylcypromine really metabolized to amphetamine? J Clin Psychiatry: 1992; 53 450 451
73. Baker G., Urichuk L., McKenna K. et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol: 1999; 19 411 426 (Pubitemid 29205394)
74. Cohen R., Campbell I., Dauphin M. et al. Changes in alpha- and beta-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. Neuropharmacology: 1982; 21 293 298 (Pubitemid 12158495)
75. Siever L., Uhde T., Murphy D. L. Possible subsensitization of alpha 2-adrenergic receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients. Psychiatry Res: 1982; 293 302 (Pubitemid 12011990)
76. Casillas A., Clark L. Dependency, impulsivity, and self-harm: traits hypothesized to underline the association between cluster B personality disorder and substance abuse disorders. J Pers Disord: 2002; 16 424 436 (Pubitemid 35403719)
77. Cohen P., Chen H., Crawford T. et al. Personality disorders in early adolescence and the development of later substance use disorders in the general population. Drug Alcohol Depend: 2007; 88 01 S71 S84 (Pubitemid 46282353)
78. Calverley D., Baker G., Coutts R. et al. A method for measurement of tranylcypromine in rat brain regions using gas chromatography with electron capture detection. Biochem Pharmacol: 1981; 30 861 867 (Pubitemid 11096137)
79. Kang G., Chung S. Identification of N-acetyl and hydroxylated N-acetyltranylcypromine from tranylcypromine-dosed rat urine. Arch Pharm Res (Korea): 1984; 7 65 68
80. Baker G., Hampson D., Coutts R. et al. Detection and quantification of a ring-hydroxylated metabolite of the antidepressant drug tranylcypromine. J Neural Transm: 1986; 65 233 243 (Pubitemid 16073146)
81. 14 in the rat. J Med Chem: 1965; 6 621 624
82. Gillman P. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol: 2011; 31
83. Yun C., Shimada T., Guengerich F. Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol Pharmacol: 1991; 40 679 685
84. Mallinger A., Edwards D., Himmelhoch J. et al. Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clin Pharmacol Ther: 1986; 40 444 450 (Pubitemid 16009047)
85. Bieck P., Antonin K. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl: 1989; 28 21 31
86. Mawdsley J. "Parstelino". A case of fatal overdose. Med J Austr: 1968; 2 292